Back to results
US 9,850,486 B2Granted
Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA
AssigneeDicerna Pharmaceuticals, Inc.
InventorsBob D. Brown, Henryk T. Dudek
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds, compositions, and methods useful for reducing CKAP5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Claims55
An isolated nucleic acid comprising an oligonucleotide strand of 19-50 nucleotides in length, wherein said oligonucleotide strand is complementary to SEQ ID NO:
- 2355 (5′-CCCAACAAGAACUAGAAGCUA-3′) along at least 19 nucleotides of said oligonucleotide strand length and reduces CKAP5 target mRNA expression when said nucleic acid is introduced into a mammalian cell.
An isolated dsNA comprising first and second nucleic acid strands, wherein said first strand is 15-35 nucleotides in length and said second strand of said dsNA is 19-50 nucleotides in length, wherein said second nucleic acid strand is complementary to SEQ ID NO:
- 2355 (5′-CCCAACAAGAACUAGAAGCUA-3′) along at least 19 consecutive nucleotides of said second strand length and said dsNA reduces CKAP5 target mRNA expression when said double stranded nucleic acid is introduced into a mammalian cell.
Dependencies are inferred from the claim text.